A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Vergote, Ignace; Schilder, Russell J.; Pippitt, Charles H. Jret al.
[en] OBJECTIVE: To examine the tolerability and antitumor activity of trebananib plus pegylated liposomal doxorubicin (PLD) or topotecan in recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. METHODS: In this open-label phase 1b study, patients received trebananib 10mg/kg or 15mg/kg IV QW plus PLD 50mg/m(2) (cohorts A1 and A3, respectively) or topotecan 4mg/m(2) (cohorts B1 and B3, respectively). Endpoints were dose-limiting toxicity (DLT; primary); treatment-emergent adverse events (AEs), overall response rate, anti-trebananib antibodies, and pharmacokinetics (secondary). RESULTS: 103 patients were enrolled. One patient in A1 and B1 had DLTs. Across all cohorts, the most common AEs were nausea, fatigue, and peripheral edema. Across both trebananib plus PLD cohorts (A1/A3), grade 4 AEs were pulmonary embolism, disease progression, and anemia. Two patients had grade 5 intestinal perforation (n=1) and sudden death (n=1). Across both trebananib plus topotecan cohorts (B1/B3), grade 4 AEs were neutropenia, hypokalemia, decreased granulocyte count, chest pain, dyspnea, decreased neutrophil count, and pulmonary embolism. Two patients had grade 5 disease progression. One patient had grade 5 pleural effusion associated with progressive disease. Confirmed objective response rates were 36.0% (A1), 34.8% (A3), 16.7% (B1), and 0.0% (B3). Median progression-free survival duration (months) was 7.4 (A1), 7.1 (A3), 3.5 (B1), and 3.1 (B3), respectively. No drug-drug interactions were apparent. CONCLUSIONS: Trebananib 10mg/kg and 15mg/kg IV QW plus PLD or topotecan appear to have acceptable toxicity profiles in recurrent platinum-resistant or partially platinum-sensitive ovarian cancer. Antitumor activity was evident across all cohorts.
Disciplines :
Surgery
Author, co-author :
Vergote, Ignace
Schilder, Russell J.
Pippitt, Charles H. Jr
Wong, Shirley
Gordon, Alan N.
Scudder, Sidney
Kridelka, Frédéric ; Université de Liège - ULiège > Département des sciences cliniques > Gynécologie-Obstétrique
A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
Publication date :
2014
Journal title :
Gynecologic Oncology
ISSN :
0090-8258
eISSN :
1095-6859
Publisher :
Elsevier, Atlanta, United States - California
Volume :
135
Issue :
1
Pages :
25-33
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2014 Elsevier Inc. All rights reserved.
P.-L. María Eva, C. Teresa, G. Jesús García, and J. Mónica Role of pegylated liposomal doxorubicin (Caelyx) in the treatment of relapsing ovarian cancer Anticancer Drugs 18 2007 611 617
M. Markman, R. Rothman, T. Hakes, B. Reichman, W. Hoskins, and S. Rubin Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin J Clin Oncol 9 1991 389 393
G. Ferrandina, M. Ludovisi, D. Lorusso, S. Pignata, E. Breda, and A. Savarese Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer J Clin Oncol 26 2008 890 896
M. Markman Pegylated liposomal doxorubicin: appraisal of its current role in the management of epithelial ovarian cancer Cancer Manag Res 3 2011 219 225
A.N. Gordon, M. Tonda, S. Sun, and W. Rackoff Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer Gynecol Oncol 95 2004 1 8
M.A. Bookman Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy Oncologist 4 1999 87 94
J. Folkman Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6 2007 273 286
E. Pujade-Lauraine, F. Hilpert, B. Weber, A. Reuss, A. Poveda, and G. Kristensen Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial J Clin Oncol 2014 10.1200/JCO.2013.51.4489
P. Witteveen, A. Lortholary, T. Fehm, A. Poveda, A. Reuss, and H. Havsteen Final overall survival (OS) results from AURELIA, an open-label randomized phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC) Eur J Cancer 49 Suppl. 3 2013
P. Harter, J. Sehouli, R. Kimmig, J. Rau, F. Hilpert, and C. Kurzeder Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO study group (AGO-OVAR 2.13) Invest New Drugs 31 2013 1499 1504
P.C. Maisonpierre, C. Suri, P.F. Jones, S. Bartunkova, S.J. Wiegand, and C. Radziejewski Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis Science 277 1997 55 60
C. Suri, P.F. Jones, S. Patan, S. Bartunkova, P.C. Maisonpierre, and S. Davis Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis Cell 87 1996 1171 1180
L. Eklund, and B.R. Olsen Tie receptors and their angiopoietin ligands are context-dependent regulators of vascular remodeling Exp Cell Res 312 2006 630 641
J. Oliner, H. Min, J. Leal, D. Yu, S. Rao, and E. You Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2 Cancer Cell 6 2004 507 516
A. Coxon, J. Bready, H. Min, S. Kaufman, J. Leal, and D. Yu Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody Mol Cancer Ther 9 2010 2641 2651
R.S. Herbst, D. Hong, L. Chap, R. Kurzrock, E. Jackson, and J.M. Silverman Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors J Clin Oncol 27 2009 3557 3565
B.Y. Karlan, A.M. Oza, G.E. Richardson, D.M. Provencher, V.L. Hansen, and M. Buck Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer J Clin Oncol 30 2012 362 371
B.J. Monk, A. Poveda, I. Vergote, F. Raspagliesi, K. Fujiwara, and D.S. Bae A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1 Eur J Cancer 49 Suppl. 3 2013
B. Karabulut, C. Sezgin, M.C. Terek, R. Uslu, U.A. Sanli, and L. Akman Topotecan in platinum-resistant epithelial ovarian cancer Chemotherapy 51 2005 347 351
P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
G.J. Rustin, M. Marples, A.E. Nelstrop, M. Mahmoudi, and T. Meyer Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels J Clin Oncol 19 2001 4054 4057
F. Abushahin, D.K. Singh, J.R. Lurain, E.C. Grendys, A.W. Rademaker, and J.C. Schink Weekly topotecan for recurrent platinum resistant ovarian cancer Gynecol Oncol 108 2008 53 57
R. Morris, R.D. Alvarez, S. Andrews, J. Malone, C. Bryant, and L.K. Heilbrun Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers Gynecol Oncol 109 2008 346 352
Z.D. Zhong, S. Dinnogen, M. Hokom, C. Ray, D. Weinreich, and S.J. Swanson Identification and inhibition of drug target interference in immunogenicity assays J Immunol Methods 355 2010 21 28
M.B. Bass, S.I. Sherman, M.J. Schlumberger, M.T. Davis, L. Kivman, and H.M. Khoo Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer J Clin Endocrinol Metab 95 2010 5018 5027
A.N. Gordon, J.T. Fleagle, D. Guthrie, D.E. Parkin, M.E. Gore, and A.J. Lacave Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan J Clin Oncol 19 2001 3312 3322
D.G. Mutch, M. Orlando, T. Goss, M.G. Teneriello, A.N. Gordon, and S.D. McMeekin Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer J Clin Oncol 25 2007 2811 2818
G. Blackledge, F. Lawton, C. Redman, and K. Kelly Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials Br J Cancer 59 1989 650 653
J. Ledermann, and F. Raja Management strategies for partially platinum-sensitive ovarian cancer Am J Cancer 5 2006 341 354
R. Ramasubbaiah, S.M. Perkins, J. Schilder, C. Whalen, C.S. Johnson, and M. Callahan Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group Gynecol Oncol 123 2011 499 504
C.F. Verschraegen, S. Czok, C.Y. Muller, L. Boyd, S.J. Lee, and T. Rutledge Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer Ann Oncol 23 2012 3104 3110
T. Safra, S. Groshen, S. Jeffers, D.D. Tsao-Wei, L. Zhou, and L. Muderspach Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin: analysis of toxicities and predictors of outcome Cancer 91 2001 90 100
T.J. Herzog, M.W. Sill, J.L. Walker, D. O'Malley, M. Shahin, and K. DeGeest A phase II study of two topotecan regimens evaluated in recurrent platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group study (GOG 146Q) Gynecol Oncol 120 2011 454 458
B. Rini, C. Szczylik, N.M. Tannir, P. Koralewski, P. Tomczak, and A. Deptala AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study Cancer 118 2012 6152 6161
M.M. Eatock, N.C. Tebbutt, C.L. Bampton, A.H. Strickland, M. Valladares-Ayerbes, and A. Swieboda-Sadlej Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer Ann Oncol 24 2013 710 718
B.J. Monk, A. Poveda, I. Vergote, F. Raspagliesi, K. Fujiwara, and D.S. Bae A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer: TRINOVA-1 European Cancer Congress 2013; Sep 27-Oct 1; Amsterdam, Netherlands 2013
I. Vergote, A. Oaknin Benzaquen, J. Baurain, S. Ananda, S. Wong, and X. Yang A phase 1b study of AMG 386 plus paclitaxel and carboplatin in ovarian cancer patients undergoing primary or interval debulking surgery Ann Oncol 23 Suppl. 9 2012
M. Peeters, A.H. Strickland, M. Lichinitser, A.V. Suresh, G. Manikhas, and J. Shapiro A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma Br J Cancer 108 2013 503 511
I.B. Vergote, A.O. Benzaquen, J. Baurain, S. Ananda, S. Wong, and X. Yang A phase 1b study of AMG 386 plus paclitaxel and carboplatin in ovarian cancer patients undergoing primary or interval debulking surgery Ann Oncol 23 2012 975PD
A.M. Poveda, F. Selle, F. Hilpert, A. Reuss, A. Pasic, and A. Savarese Weekly paclitaxel (PAC), pegylated liposomal doxorubicin (PLD) or topotecan (TOP) ± bevacizumab (BEV) in platinum (PT)-resistant recurrent ovarian cancer (OC): analysis by chemotherapy (CT) cohort in the GCIG Aurelia randomized phase III trial Ann Oncol 23 Suppl. 9 2012 LBA26